Children's Oncology Groups's 2023 Blueprint for Research: Developmental Therapeutics

The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histo...

Full description

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 70; no. Suppl 6; p. e30563
Main Authors Fox, Elizabeth, Parsons, D Williams, Weigel, Brenda J
Format Journal Article
LanguageEnglish
Published 10.07.2023
Online AccessGet full text

Cover

More Information
Summary:The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through clinical and translational research. DVL has focused on evaluating the activity of targeted therapy and has evolved from trials with multiple histology strata to biomarker selected Phase 2 trials. These trials have included single agent studies to evaluate agents such as cabozantinib in multi-disease cohorts, to trametinib, larotrectinib and lorvotuzumab in disease specific cohorts as well as the pediatric MATCH study including multiple single agents targeted for biomarker selected pediatric tumors. The ongoing vision and direction of DVL is to support the disease committees of COG to develop novel agents and combinations to advance the care of children with cancer.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.30563